KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $8.5 million.

  • Novavax's Share-based Compensation fell 29.05% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.5 million, marking a year-over-year decrease of 27.86%. This contributed to the annual value of $48.2 million for FY2024, which is 43.59% down from last year.
  • Per Novavax's latest filing, its Share-based Compensation stood at $8.5 million for Q3 2025, which was down 7.22% from $9.2 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Share-based Compensation registered a high of $53.1 million during Q2 2021, and its lowest value of $8.5 million during Q3 2025.
  • For the 3-year period, Novavax's Share-based Compensation averaged around $14.7 million, with its median value being $12.0 million (2024).
  • As far as peak fluctuations go, Novavax's Share-based Compensation surged by 1,238.21% in 2021, and later slumped by 59.66% in 2024.
  • Over the past 5 years, Novavax's Share-based Compensation (Quarterly) stood at $32.2 million in 2021, then dropped by 13.66% to $27.8 million in 2022, then tumbled by 43.63% to $15.7 million in 2023, then crashed by 33.27% to $10.4 million in 2024, then declined by 29.05% to $8.5 million in 2025.
  • Its last three reported values are $8.5 million in Q3 2025, $9.2 million for Q2 2025, and $10.3 million during Q1 2025.